TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
时间：2024-11-14 06:00:00 市场： 综合 美股
Travere Therapeutics: Entered Amended & Restated Agreement of Upto $100 Mln in Common Stock Offering
时间：2024-10-31 20:54:47 市场： 美股 综合
Travere Therapeutics Inc: Interim Data From Spartacus Study Demonstrated That Filspari, When Added to Stable Sglt2i, Was Generally Well Tolerated
时间：2024-10-26 19:01:51 市场： 美股 综合
CSL Vifor and Travere Therapeutics Announce Swissmedic Approval of Filspari® (Sparsentan) for the Treatment of Iga Nephropathy
时间：2024-10-17 14:30:03 市场： 美股 综合
Travere Therapeutics Inc : Leerink Partners Raises Target Price to $40 From $20
时间：2024-10-11 18:11:42 市场： 美股 综合
Travere Therapeutics Inc : Leerink Partners Raises Target Price to $40 From $20
时间：2024-10-11 18:03:53 市场： 美股 综合
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 Harmony Study of Pegtibatinase Related to Commercial Manufacturing Scale-up
时间：2024-09-27 04:01:00 市场： 综合 美股